BeOne Medicines (ONC) Reports Positive Phase 1/2 Results for Sonrotoclax in MCL

BeOne Medicines Ltd. (NASDAQ:ONC) ranks among the best-performing European stocks to invest in. On August 29, BeOne Medicines Ltd. (NASDAQ:ONC) stated that the Phase 1/2 research of sonrotoclax had reached its main objective of overall response rate in patients with relapsed or refractory mantle cell lymphoma.

Photo by National Cancer Institute on Unsplash

The trial showed clinically relevant responses in the extensively pretreated patient category. Promising outcomes were also observed for secondary goals, including progression-free survival, response duration, and a complete response rate.

BeOne Medicines Ltd. (NASDAQ:ONC) plans on sending the data for possible approval to the U.S. Food and Drug Administration as well as other international regulatory agencies. The company has already filed new drug applications with China’s National Medical Products Administration for sonrotoclax in chronic lymphocytic leukemia and relapsed or refractory mantle cell lymphoma.

BeOne Medicines Ltd. (NASDAQ:ONC) is a global biotechnology company that specializes in oncology medicines, particularly for blood cancers and solid tumors.

While we acknowledge the potential of ONC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ONC and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.